{"schema_version":"secwatch.filing_event.v1","accession":"0001091818-26-000124","form_type":"8-K","ticker":"BFNH","cik":"0001310488","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","filed_at":"2026-08-14T19:23:23+00:00","discovered_at":"2026-08-14T19:24:00.253693+00:00","generated_at":"2026-08-14T19:24:05.276939+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BioForce NanoSciences appoints interim CEO, adds director and advisory board members","bullets":["Richard Kaiser appointed interim CEO on June 17, 2026; he remains CFO, Secretary, and Director.","Scott Mager appointed General Counsel on May 19, 2026, and Director on June 15, 2026.","Advisory Board established May 19, 2026; Stuart Yarbrough and Edward Mathias appointed for 3-year terms ending May 19, 2029.","Yarbrough is CPA with 20+ years at Ernst & Young and BDO; Mathias is senior advisor to Carlyle Group."],"urls":{"canonical":"https://secwatch.observer/filing/0001091818-26-000124","json":"https://secwatch.observer/filing/0001091818-26-000124.json","markdown":"https://secwatch.observer/filing/0001091818-26-000124.md","text":"https://secwatch.observer/filing/0001091818-26-000124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1310488/000109181826000124/0001091818-26-000124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1310488/000109181826000124/bfnh-08142026_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T19:24:05.276939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}